Fluor is providing engineering, procurement, construction management, commissioning and qualification services for Bayer’s new cell culture technology center, which is under construction in Berkeley, Calif. The biopharmaceutical manufacturing facility will produce future therapies for oncology and other diseases. It is scheduled to be ready for first clinical production in late 2021. Fluor, which didn’t file a survey with ENR this year for the first time in decades due to SEC accounting review rules, began its conceptual study and front-end engineering design for the project in 2018. The project, which broke ground in May 2019, is being constructed at Bayer’s Berkeley site using land from a demolished office building. Bayer selected GE Healthcare to provide its single-use technology platform, which is being incorporated into the project through a collaborative subcontract to Fluor. Under the agreement, GE Healthcare supplies all major unit operations, systems and ancillary equipment and components. Fluor’s scope also includes utility process integration for the entire facility. Fluor’s San Francisco office is leading the project with support from the company’s offices in Greenville, S.C., and Gliwice, Poland.
Related Link: ENR 2020 Top Design Firms Sourcebook (subscription required)